PDF(804 KB)
Prospects for China’s Pharmaceutical Industry Development During the 15th Five-Year Plan Period
Huili CAO, Boyang LI, Guoxu WEI
Acta Academiae Medicinae Sinicae ›› 2026, Vol. 48 ›› Issue (3) : 393-397.
PDF(804 KB)
Abbreviation (ISO4): Acta Academiae Medicinae Sinicae
Editor in chief: Xuetao CAO
PDF(804 KB)
Prospects for China’s Pharmaceutical Industry Development During the 15th Five-Year Plan Period
The pharmaceutical industry is a strategic sector bearing on national economy,development,and security.It represents one of the fields featuring highly active scientific innovation,fierce international competition,and high policy attention.Amidst profound adjustments in the global pharmaceutical landscape and the deep advancement of a new round of scientific and technological revolution and industrial transformation,the 15th Five-Year Plan period marks a critical stage for China’s pharmaceutical industry to achieve high-quality development.This article systematically analyzes the characteristics and strategic positioning of the pharmaceutical industry,reviews the development landscape and trends of the global pharmaceutical industry,and objectively summarizes China’s current status of this industry in terms of industrial scale,innovation capability,industrial clustering,and internationalization.The study suggests that during the 15th Five-Year Plan period,China’s pharmaceutical industry faces five major new situations—new strategic positioning,new market demands,emerging technologies,fresh growth drivers,and a reshaped industrial landscape,with opportunities outweighing challenges.To achieve high-quality development during the 15th Five-Year Plan period,the industry should adhere to five principles:prioritizing scale-driven expansion to enlarge industrial footprint,boosting technological foundation to anchor innovation-led development,advancing business model innovation to foster new application scenarios,adhering to people-centered development to ramp up high-quality product supply,and optimizing the industrial ecosystem to refine supporting guarantee systems.
pharmaceutical industry / biomedical industry / the 15th Five-Year Plan period / emerging pillar industry / innovation / prospect
| [1] |
|
| [2] |
IQVIA. IQVIA early bird:2025 revealed-the trends shaping pharma’s future[EB/OL].(2026-03-11)[2026-06-09]. https://www.iqvia.com/blogs/2026/03/iqvia-early-bird-2025-revealed.
|
| [3] |
IQVIA. Global medicine spending and usage trends outlook to 2026[R]. Durham: IQVIA Institute for Human Data Science, 2022.
|
| [4] |
IFPMA,WifOR Institute. The economic impact of the global pharmaceutical industry[R]. Geneva: International Federation of Pharmaceutical Manufacturers & Associations, 2024.
|
| [5] |
|
| [6] |
6Wresearch. Global biologics market (2026-2032)[R/OL].(2025-04)[2026-06-24]. https://www.6wresearch.com/industry-report/global-biologics-market.
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
薛静文. 未来五年,我国医药工业发展方向已明[EB/OL].(2025-12-08)[2026-06-24]. https://www.cnpharm.com/c/2025-12-08/1086218.shtml.
|
| [11] |
中国医药企业管理协会. 2025年医药工业经济运行情况[R]. 北京: 中国医药企业管理协会, 2026.
|
| [12] |
中国医药统计网. 2015年1-12月份分行业生产情况[EB/OL].(2016-02-03)[2026-06-24]. https://www.yytj.org.cn/article.aspx?id=481.
|
| [13] |
Citeline. 2025 pharmaceutical R&D annual review[R]. New York: Citeline,2025.
|
| [14] |
清华大学药品监管科学研究院,医药魔方. 全球视野下的中国创新药产业:十年回顾与展望[R]. 北京: 清华大学, 2025.
|
利益冲突 所有作者声明无利益冲突
/
| 〈 |
|
〉 |